Clinical Trial Update: The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III trial evaluating 3% cannabidiol (CBD) cream for Epidermolysis Bullosa has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• 3% Cannabidiol (CBD) cream (cannabidiol)

Snippet

Sponsor: Elena Pope | Conditions: Epidermolysis Bullosa, Pain | Phase 2, Phase 3 | Status: WITHDRAWN